Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: Implications for development of an atheroprotective vaccine

Journal of Lipid Research

Volumn 55, Issue 10, 2014, Pages 2137-2155

  Gonen, Ayelet ^a   Hansen, Lotte F ^a   Turner, William W ^b   Montano, Erica N ^a   Que, Xuchu ^a   Rafia, Apaïs ^a   Chou, Meng Yun ^a   Wiesner, Philipp ^a   Tsiantoulas, Dimitrios ^c,d   Corr, Maripat ^a   VanNieuwenhze, Michael S ^b   Tsimikas, Sotirios ^a   Binder, Christoph J ^a,c,d   Witztum, Joseph L ^a   Hartvigsen, Karsten ^a,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adaptive immunity; Humoral immunity; Malondialdehyde acetaldehyde adducts; Oxidation specific epitopes

Indexed keywords

EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; HAPTEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MALONALDEHYDE MODIFIED LOW DENSITY LIPOPROTEIN; MALONDIALDEHYDE ACETALDEHYDE MODIFIED MOUSE SERUM ALBUMIN; MALONDIALDEHYDE MODIFIED BOVINE SERUM ALBUMIN; MALONDIALDEHYDE MODIFIED MOUSE SERUM ALBUMIN; MOUSE SERUM ALBUMIN; OXIDATION SPECIFIC EPITOPE; PROPAL MODIFIED MOUSE SERUM ALBUMIN; UNCLASSIFIED DRUG; VACCINE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B LYMPHOCYTE; BODY WEIGHT; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNIZATION; LIPID BLOOD LEVEL; LIPID OXIDATION; MALE; NEWBORN; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN MODIFICATION; TH2 CELL; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MOUSE; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; HAPTENS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MICE; MICE, KNOCKOUT; TH2 CELLS; VACCINES;

EID: 84907486115     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M053256     Document Type: Article

References (48)

1. Tabas, I., and C. K. Glass. 2013. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 339: 166-172.
2. Glass, C. K., and J. L. Witztum. 2001. Atherosclerosis. The road ahead. Cell. 104: 503-516.
3. Lichtman, A. H., C. J. Binder, S. Tsimikas, and J. L. Witztum. 2013. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J. Clin. Invest. 123: 27-36.
4. Libby, P., P. M. Ridker, and G. K. Hansson. 2011. Progress and challenges in translating the biology of atherosclerosis. Nature. 473: 317-325.
5. Miller, Y. I., S. H. Choi, P. Wiesner, L. Fang, R. Harkewicz, K. Hartvigsen, A. Boullier, A. Gonen, C. J. Diehl, X. Que, et al. 2011. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108: 235-248.
6. Tsimikas, S., W. Palinski, and J. L. Witztum. 2001. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21: 95-100.
7. Palinski, W., E. Miller, and J. L. Witztum. 1995. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA. 92: 821-825.
8. Freigang, S., S. Horkko, E. Miller, J. L. Witztum, and W. Palinski. 1998. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18: 1972-1982.
9. Binder, C. J., K. Hartvigsen, M. K. Chang, M. Miller, D. Broide, W. Palinski, L. K. Curtiss, M. Corr, and J. L. Witztum. 2004. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114: 427-437.
10. Ameli, S., A. Hultgardh-Nilsson, J. Regnstrom, F. Calara, J. Yano, B. Cercek, P. K. Shah, and J. Nilsson. 1996. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16: 1074-1079.
11. Zhou, X., G. Caligiuri, A. Hamsten, A. K. Lefvert, and G. K. Hansson. 2001. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 108-114.
12. Binder, C. J., M. K. Chang, P. X. Shaw, Y. I. Miller, K. Hartvigsen, A. Dewan, and J. L. Witztum. 2002. Innate and acquired immunity in atherogenesis. Nat. Med. 8: 1218-1226.
13. Hansson, G. K., and J. Nilsson. 2009. Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin. Immunopathol. 31: 95-101.
14. Nilsson, J., H. Björkbacka, and G. N. Fredrikson. 2012. Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential. Curr. Opin. Lipidol. 23: 422-428.
15. Thiele, G. M., S. Worrall, D. J. Tuma, L. W. Klassen, T. A. Wyatt, and N. Nagata. 2001. The chemistry and biological effects of malondialdehyde-acetaldehyde adducts. Alcohol. Clin. Exp. Res. 25: 218S-224S.
16. Tuma, D. J., M. L. Kearley, G. M. Thiele, S. Worrall, A. Haver, L. W. Klassen, and M. F. Sorrell. 2001. Elucidation of reaction scheme describing malondialdehyde-acetaldehyde-protein adduct formation. Chem. Res. Toxicol. 14: 822-832.
17. Duryee, M. J., L. W. Klassen, C. S. Schaffert, D. J. Tuma, C. D. Hunter, R. P. Garvin, D. R. Anderson, and G. M. Thiele. 2010. Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis. Free Radic. Biol. Med. 49: 1480-1486.
18. Habeeb, A. F. 1966. Chemical evaluation of conformational differences in native and chemically modified proteins. Biochim. Biophys. Acta. 115: 440-454.
19. Chou, M. Y., L. Fogelstrand, K. Hartvigsen, L. F. Hansen, D. Woelkers, P. X. Shaw, J. Choi, T. Perkmann, F. Backhed, Y. I. Miller, et al. 2009. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J. Clin. Invest. 119:1335-1349.
20. Binder, C. J., S. Horkko, A. Dewan, M. K. Chang, E. P. Kieu, C. S. Goodyear, P. X. Shaw, W. Palinski, J. L. Witztum, and G. J. Silverman. 2003. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9: 736-743.
21. Tsimikas, S., A. Miyanohara, K. Hartvigsen, E. Merki, P. X. Shaw, M. Y. Chou, J. Pattison, M. Torzewski, J. Sollors, T. Friedmann, et al. 2011. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J. Am. Coll. Cardiol. 58: 1715-1727.
22. Zlot, C. H., L. M. Flynn, M. M. Veniant, E. Kim, M. Raabe, S. P. McCormick, P. Ambroziak, L. M. McEvoy, and S. G. Young. 1999. Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. J. Lipid Res. 40: 76-84.
23. Hartvigsen, K., C. J. Binder, L. F. Hansen, A. Rafia, J. Juliano, S. Horkko, D. Steinberg, W. Palinski, J. L. Witztum, and A. C. Li. 2007. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 27: 878-885.
24. Montano, E. N., A. Boullier, F. Almazan, C. J. Binder, J. L. Witztum, and K. Hartvigsen. 2013. Development and application of a nonradioactive binding assay of oxidized low-density lipoprotein to macrophage scavenger receptors. J. Lipid Res. 54: 3206-3214.
25. Thiele, G. M., M. J. Duryee, M. S. Willis, M. F. Sorrell, T. L. Freeman, D. J. Tuma, and L. W. Klassen. 2004. Malondialdehyde-acetaldehyde (MAA) modified proteins induce pro-inflammatory and pro-fibrotic responses by liver endothelial cells. Comp. Hepatol. 3 (Suppl. 1): S25.
26. Weismann, D., K. Hartvigsen, N. Lauer, K. L. Bennett, H. P. Scholl, P. Charbel Issa, M. Cano, H. Brandstatter, S. Tsimikas, C. Skerka, et al. 2011. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature. 478: 76-81.
27. Khallou-Laschet, J., E. Tupin, G. Caligiuri, B. Poirier, N. Thieblemont, A. T. Gaston, M. Vandaele, J. Bleton, A. Tchapla, S. V. Kaveri, et al. 2006. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. Atherosclerosis. 184: 330-341.
28. Shaw, P. X., S. Horkko, M. K. Chang, L. K. Curtiss, W. Palinski, G. J. Silverman, and J. L. Witztum. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105: 1731-1740.
29. Haberland, M. E., A. M. Fogelman, and P. A. Edwards. 1982. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc. Natl. Acad. Sci. USA. 79: 1712-1716.
30. Wang, C., S. P. Turunen, O. Kummu, M. Veneskoski, J. Lehtimäki, A. E. Nissinen, and S. Hörkkö. 2013. Natural antibodies of newborns recognize oxidative stress-related malondialdehyde acetaldehyde adducts on apoptotic cells and atherosclerotic plaques. Int. Immunol. 25: 575-587.
31. Rosenfeld, M. E., W. Palinski, S. Yla-Herttuala, S. Butler, and J. L. Witztum. 1990. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10: 336-349.
32. van Dijk, R. A., F. Kolodgie, A. Ravandi, G. Leibundgut, P. P. Hu, A. Prasad, E. Mahmud, E. Dennis, L. K. Curtiss, J. L. Witztum, et al. 2012. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J. Lipid Res. 53: 2773-2790.
33. Caligiuri, G., J. Khallou-Laschet, M. Vandaele, A. T. Gaston, S. Delignat, C. Mandet, H. V. Kohler, S. V. Kaveri, and A. Nicoletti. 2007. Phosphorylcholine-targeting immunization reduces atherosclerosis. J. Am. Coll. Cardiol. 50: 540-546.
34. Billiau, A., and P. Matthys. 2001. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 70: 849-860.
35. Willis, M. S., L. W. Klassen, D. L. Carlson, C. F. Brouse, and G. M. Thiele. 2004. Malondialdehyde-acetaldehyde haptenated protein binds macrophage scavenger receptor(s) and induces lysosomal damage. Int. Immunopharmacol. 4: 885-899.
36. Duryee, M. J., T. L. Freeman, M. S. Willis, C. D. Hunter, B. C. Hamilton III, H. Suzuki, D. J. Tuma, L. W. Klassen, and G. M. Thiele. 2005. Scavenger receptors on sinusoidal liver endothelial cells are involved in the uptake of aldehyde-modified proteins. Mol. Pharmacol. 68: 1423-1430.
37. Amir, S., K. Hartvigsen, A. Gonen, G. Leibundgut, X. Que, E. Jensen-Jarolim, O. Wagner, S. Tsimikas, J. L. Witztum, and C. J. Binder. 2012. Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. J. Lipid Res. 53: 1316-1326.
38. Chang, M. K., C. J. Binder, Y. I. Miller, G. Subbanagounder, G. J. Silverman, J. A. Berliner, and J. L. Witztum. 2004. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J. Exp. Med. 200: 1359-1370.
39. Thiele, G. M., M. J. Duryee, M. S. Willis, D. J. Tuma, S. J. Radio, C. D. Hunter, C. S. Schaffert, and L. W. Klassen. 2010. Autoimmune hepatitis induced by syngeneic liver cytosolic proteins biotransformed by alcohol metabolites. Alcohol. Clin. Exp. Res. 34: 2126-2136.
40. Herbin, O., H. Ait-Oufella, W. Yu, G. N. Fredrikson, B. Aubier, N. Perez, V. Barateau, J. Nilsson, A. Tedgui, and Z. Mallat. 2012. Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 32: 605-612.
41. Libby, P., A. H. Lichtman, and G. K. Hansson. 2013. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 38: 1092-1104.
42. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
43. Witztum, J. L., U. P. Steinbrecher, Y. A. Kesaniemi, and M. Fisher. 1984. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc. Natl. Acad. Sci. USA. 81: 3204-3208.
44. Steinbrecher, U. P., and J. L. Witztum. 1984. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes. 33: 130-134.
45. Wiklund, O., J. L. Witztum, T. E. Carew, R. C. Pittman, R. L. Elam, and D. Steinberg. 1987. Turnover and tissue sites of degradation of glucosylated low density lipoprotein in normal and immunized rabbits. J. Lipid Res. 28: 1098-1109.
46. Witztum, J. L., and A. H. Lichtman. 2014. The influence of innate and adaptive immune responses on atherosclerosis. Annu. Rev. Pathol. 9: 73-102.
47. Tse, K., A. Gonen, J. Sidney, H. Ouyang, J. L. Witztum, A. Sette, H. Tse, and K. Ley. 2013. Atheroprotective vaccination with MHC-II restricted peptides from apoB-100. Front. Immunol. 4: 493.
48. Hermansson, A., D. K. Johansson, D. F. Ketelhuth, J. Andersson, X. Zhou, and G. K. Hansson. 2011. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation. 123: 1083-1091.